0001179110-21-008894.txt : 20210922 0001179110-21-008894.hdr.sgml : 20210922 20210922175644 ACCESSION NUMBER: 0001179110-21-008894 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210921 FILED AS OF DATE: 20210922 DATE AS OF CHANGE: 20210922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANGO SUJAY CENTRAL INDEX KEY: 0001336503 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 211270419 MAIL ADDRESS: STREET 1: 1028 CHAMBERS COURT CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2021-09-21 0 0001280600 ACCELERON PHARMA INC XLRN 0001336503 KANGO SUJAY 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2021-09-21 4 M 0 5000 40.61 A 23509 D Common Stock 2021-09-21 4 S 0 5000 150.03 D 18509 D Option to Purchase Common Stock 40.61 2021-09-21 4 M 0 5000 0 D 2028-03-01 Common Stock 5000 30000 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.45 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter. /s/ Adam M. Veness, as attorney-in-fact for Sujay Kango 2021-09-22